Estrogen and progesterone receptors: from molecular structures to clinical targets

Research involving estrogen and progesterone receptors (ER and PR) have greatly contributed to our understanding of cell signaling and transcriptional regulation. In addition to the classical ER and PR nuclear actions, new signaling pathways have recently been identified due to ER and PR association with cell membranes and signal transduction proteins. Bio-informatics has unveiled how ER and PR recognize their ligands, selective modulators and co-factors, which has helped to implement them as key targets in the treatment of benign and malignant tumors. Knowledge regarding ER and PR is vast and complex; therefore, this review will focus on their isoforms, signaling pathways, co-activators and co-repressors, which lead to target gene regulation. Moreover it will highlight ER and PR involvement in benign and malignant diseases as well as pharmacological substances influencing cell signaling and provide established and new structural insights into the mechanism of activation and inhibition of these receptors.

[1]  D. McDonnell,et al.  The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. , 1999, Endocrinology.

[2]  Eva Enmark,et al.  Ligand-, Cell-, and Estrogen Receptor Subtype (α/β)-dependent Activation at GC-rich (Sp1) Promoter Elements* , 2000, The Journal of Biological Chemistry.

[3]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[4]  S. F. Arnold,et al.  Phosphorylation of the human estrogen receptor by mitogen-activated protein kinase and casein kinase II: Consequence on DNA binding , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  Margaret Warner,et al.  Estrogen receptors: how do they signal and what are their targets. , 2007, Physiological reviews.

[6]  J. Kato,et al.  Isoform/variant mRNAs for sex steroid hormone receptors in humans , 2003, Trends in Endocrinology & Metabolism.

[7]  J. Gustafsson,et al.  Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. , 2000, The Journal of biological chemistry.

[8]  B. O’Malley,et al.  Reproductive functions of progesterone receptors. , 2002, Recent progress in hormone research.

[9]  J. Blenis,et al.  pp90rsk1 Regulates Estrogen Receptor-Mediated Transcription through Phosphorylation of Ser-167 , 1998, Molecular and Cellular Biology.

[10]  R. Gleason,et al.  Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. , 1994, Human reproduction.

[11]  E. Kalkhoven,et al.  Isoforms of steroid receptor co‐activator 1 differ in their ability to potentiate transcription by the oestrogen receptor , 1998, The EMBO journal.

[12]  E. Baulieu,et al.  Subunit composition of the molybdate-stabilized "8-9 S" nontransformed estradiol receptor purified from calf uterus. , 1987, The Journal of biological chemistry.

[13]  R. Vadlamudi,et al.  Functional Interactions between the Estrogen Receptor Coactivator PELP1/MNAR and Retinoblastoma Protein* , 2003, Journal of Biological Chemistry.

[14]  K. Horwitz,et al.  A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. , 1994, Molecular endocrinology.

[15]  K. Korach,et al.  Estrogen receptor null mice: what have we learned and where will they lead us? , 1999, Endocrine reviews.

[16]  T. Deuel,et al.  Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66 , 2005 .

[17]  S. Schreiber,et al.  Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase , 1997, Cell.

[18]  J. Foekens,et al.  Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer , 2000, Steroids.

[19]  Y. Yamasaki,et al.  Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. , 1994, The Journal of biological chemistry.

[20]  P. Neven,et al.  The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women , 2002, Gynecologic oncology.

[21]  C. Glass,et al.  Molecular determinants of nuclear receptor-corepressor interaction. , 1999, Genes & development.

[22]  V. Giguère,et al.  Review Nuclear Receptor Signaling | The Open Access Journal of the Nuclear Receptor Signaling Atlas The NR3B subgroup: an ovERRview , 2022 .

[23]  B. Katzenellenbogen,et al.  The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. , 1999, Molecular endocrinology.

[24]  Xiaolong Wei,et al.  MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. , 2006, Molecular cell.

[25]  D. Singleton,et al.  The F-domain of estrogen receptor-alpha inhibits ligand induced receptor dimerization , 2008, Molecular and Cellular Endocrinology.

[26]  P B Sigler,et al.  Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. , 1993, Molecular endocrinology.

[28]  P Chambon,et al.  Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. , 1990, The EMBO journal.

[29]  B. O’Malley,et al.  Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. , 1995, Genes & development.

[30]  M. Parker,et al.  Molecular Determinants of the Estrogen Receptor-Coactivator Interface , 1999, Molecular and Cellular Biology.

[31]  P. Visca,et al.  Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. , 2005, Molecular biology of the cell.

[32]  Christoph Gille,et al.  STRAP: editor for STRuctural Alignments of Proteins , 2001, Bioinform..

[33]  Heather Spencer Feigelson,et al.  Weight Gain, Body Mass Index, Hormone Replacement Therapy, and Postmenopausal Breast Cancer in a Large Prospective Study , 2004, Cancer Epidemiology Biomarkers & Prevention.

[34]  Rakesh Kumar,et al.  The role of adapter protein Shc in estrogen non-genomic action , 2004, Steroids.

[35]  R. Evans,et al.  A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.

[36]  D. McDonnell,et al.  Development of peptide antagonists that target estrogen receptor–cofactor interactions , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[37]  D. Lannigan Estrogen receptor phosphorylation , 2003, Steroids.

[38]  H. Ward Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels , 1973, British medical journal.

[39]  Paul Tempst,et al.  Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex , 1999, Nature.

[40]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[41]  Eric S Manas,et al.  Structure-based design of estrogen receptor-beta selective ligands. , 2004, Journal of the American Chemical Society.

[42]  H. Schulz,et al.  Role of Endocytosis in Cellular Uptake of Sex Steroids , 2005, Cell.

[43]  B. O’Malley,et al.  Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. , 2007, Molecular cell.

[44]  C. Clarke,et al.  Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells. , 1999, Molecular endocrinology.

[45]  E. Resnick,et al.  Ligand-independent activation of pituitary ER: dependence on PKA-stimulated pathways. , 2001, Endocrinology.

[46]  O. Silvennoinen,et al.  ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. , 2000, Molecular endocrinology.

[47]  P. Thomas,et al.  Identification of membrane progestin receptors in human breast cancer cell lines and biopsies and their potential involvement in breast cancer , 2007, Steroids.

[48]  C. Christiansen,et al.  EFFECTS OF RALOXIFENE ON BONE MINERAL DENSITY, SERUM CHOLESTEROL CONCENTRATIONS, AND UTERINE ENDOMETRIUM IN POSTMENOPAUSAL WOMEN , 1998 .

[49]  J. Ruderman,et al.  Identification of XPR-1, a progesterone receptor required for Xenopus oocyte activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Gustafsson,et al.  Structural Insights into Corepressor Recognition by Antagonist-bound Estrogen Receptors* , 2007, Journal of Biological Chemistry.

[51]  Neil J McKenna,et al.  A Steroid Receptor Coactivator, SRA, Functions as an RNA and Is Present in an SRC-1 Complex , 1999, Cell.

[52]  D. Cramer,et al.  Human progesterone receptor polymorphisms and implantation failure during in vitro fertilization. , 2003, American journal of obstetrics and gynecology.

[53]  Y. Sheng,et al.  The classical progesterone receptor mediates Xenopus oocyte maturation through a nongenomic mechanism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  B. Harvey,et al.  A Gαs protein-coupled membrane receptor, distinct from the classical oestrogen receptor, transduces rapid effects of oestradiol on [Ca2+]i in female rat distal colon , 2003, Molecular and Cellular Endocrinology.

[55]  M. Tzukerman,et al.  Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. , 1994, Molecular endocrinology.

[56]  S. Yen,et al.  Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). , 1998, American journal of obstetrics and gynecology.

[57]  Martin C Frith,et al.  Genomic targets of nuclear estrogen receptors. , 2004, Molecular endocrinology.

[58]  R. Hubbard,et al.  A structural biologist's view of the oestrogen receptor , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[59]  M. Lazar,et al.  The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors , 1999, Nature.

[60]  M. Beckmann,et al.  Proliferation and cell–cell fusion of endometrial carcinoma are induced by the human endogenous retroviral Syncytin-1 and regulated by TGF-β , 2006, Journal of Molecular Medicine.

[61]  D. Edwards,et al.  Structure of the progesterone receptor-deoxyribonucleic acid complex: novel interactions required for binding to half-site response elements. , 2006, Molecular endocrinology.

[62]  L. Sahlin,et al.  Different expression of estrogen receptors alpha and beta in human myometrium and leiomyoma during the proliferative phase of the menstrual cycle and after GnRHa treatment. , 2001, Gynecological Endocrinology.

[63]  R. Strick,et al.  Multiple effects of bioflavonoids on gene regulation, cell proliferation and apoptosis: natural compounds move into the lime light of cancer research. , 2005, Leukemia research.

[64]  B. Katzenellenbogen,et al.  Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. , 1994, The Journal of biological chemistry.

[65]  S. Koide,et al.  Understanding the human estrogen receptor-alpha using targeted mutagenesis , 2006, Molecular and Cellular Endocrinology.

[66]  Tudor I. Oprea,et al.  GPR30: a novel therapeutic target in estrogen-related disease. , 2008, Trends in pharmacological sciences.

[67]  Takashi Suzuki,et al.  Progesterone Receptor A and B Isoforms in the Human Breast and Its Disorders , 2001, Japanese journal of cancer research : Gann.

[68]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[69]  A. Jungbauer,et al.  Phytoestrogens derived from red clover: An alternative to estrogen replacement therapy? , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[70]  P. Giangrande,et al.  Mapping and Characterization of the Functional Domains Responsible for the Differential Activity of the A and B Isoforms of the Human Progesterone Receptor* , 1997, The Journal of Biological Chemistry.

[71]  K. Chwalisz,et al.  Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats. , 1996, Human Reproduction.

[72]  A. Tiltman The effect of progestins on the mitotic activity of uterine fibromyomas. , 1985, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[73]  Anthony W. Norman,et al.  Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model , 2004, Nature Reviews Drug Discovery.

[74]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[75]  Harry Hollema,et al.  Risk and prognosis of endometrial cancer after tamoxifen for breast cancer , 2000, The Lancet.

[76]  H. Croxatto Mifepristone for luteal phase contraception. , 2003, Contraception.

[77]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[78]  M. Parker,et al.  Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[80]  John A. Katzenellenbogen,et al.  The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site , 1997, Steroids.

[81]  M. Beckmann,et al.  Transcriptional analysis of steroid hormone receptors in smooth muscle uterine leiomyoma tumors of postmenopausal patients , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[82]  R. Coombes,et al.  Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. , 1999, Molecular and cellular biology.

[83]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.

[84]  M. Parker,et al.  The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. , 1993, Journal of cell science.

[85]  Simak Ali,et al.  Phosphorylation of Human Estrogen Receptor α by Protein Kinase A Regulates Dimerization , 1999, Molecular and Cellular Biology.

[86]  D. Gertig,et al.  Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[87]  V. Jordan,et al.  Chemoprevention of breast cancer with selective oestrogen-receptor modulators , 2007, Nature Reviews Cancer.

[88]  E. Weiderpass,et al.  No Association between Progesterone Receptor Gene +331G/A Polymorphism and Endometrial Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[89]  S. Jiang,et al.  Estrogen receptor corepressors -- a role in human breast cancer? , 2003, Endocrine-related cancer.

[90]  F. Gannon,et al.  Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. , 2000, The EMBO journal.

[91]  K. Korach,et al.  Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[92]  M. Beckmann,et al.  Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer. , 2001, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[93]  D. L. Bain,et al.  Nuclear receptor structure: implications for function. , 2007, Annual review of physiology.

[94]  D. Lannigan,et al.  Estradiol-induced Phosphorylation of Serine 118 in the Estrogen Receptor Is Independent of p42/p44 Mitogen-activated Protein Kinase* , 1998, The Journal of Biological Chemistry.

[95]  S. Baker,et al.  PTEN function in normal and neoplastic growth. , 2006, Cancer letters.

[96]  F. Gannon,et al.  Identification of a new isoform of the human estrogen receptor‐alpha (hER‐α) that is encoded by distinct transcripts and that is able to repress hER‐α activation function 1 , 2000 .

[97]  M. Gross,et al.  Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial , 2006, BJU international.

[98]  E. Levin,et al.  Nature of functional estrogen receptors at the plasma membrane. , 2006, Molecular endocrinology.

[99]  A. Floore,et al.  Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. , 2004, Cancer cell.

[100]  K. Horwitz,et al.  The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. , 1997, Molecular endocrinology.

[101]  Xiaolong Wei,et al.  MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α , 2006 .

[102]  F. DeMayo,et al.  Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. , 2000, Science.

[103]  G. Colditz,et al.  A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[104]  J. Gustafsson,et al.  Generation and reproductive phenotypes of mice lacking estrogen receptor beta. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[105]  Zhijian Gao,et al.  Effects of progesterone on growth factor expression in human uterine leiomyoma , 2003, Steroids.

[106]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[107]  Y. Shang Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis , 2006, Nature Reviews Cancer.

[108]  D. Dalley,et al.  Breast Cancer in Men—Should Aromatase Inhibitors Become First‐Line Hormonal Treatment? , 2008, The breast journal.

[109]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[110]  Ie-Ming Shih,et al.  Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. , 2008, American journal of obstetrics and gynecology.

[111]  D. McDonnell,et al.  The Estrogen Receptor ␤-isoform (er␤) of the Human Estrogen Receptor Modulates Er␣ Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens* , 2022 .

[112]  D. Edwards,et al.  Progesterone receptor transcription and non-transcription signaling mechanisms , 2003, Steroids.

[113]  S. Mumby,et al.  Direct interactions with G α i and G βγ mediate nongenomic signaling by estrogen receptor α . , 2007, Molecular endocrinology.

[114]  G. Mor,et al.  Low-grade endometrial stromal sarcoma: hormonal aspects. , 2003, Gynecologic oncology.

[115]  O. Park-Sarge,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Characterization of Estrogen Receptor- � (ER�) Messenger Ribonucleic Acid and Protein Expression in Rat Granulosa Cells* , 1999 .

[116]  H. Randeva,et al.  Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. , 2006, Molecular endocrinology.

[117]  C. Klinge Estrogen receptor interaction with estrogen response elements. , 2001, Nucleic acids research.

[118]  P. Kyzas,et al.  Estrogen receptor beta (ERβ) protein expression correlates with BAG-1 and prognosis in brain glial tumours , 2006, Journal of Neuro-Oncology.

[119]  A. Paulussen,et al.  Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer. , 2006, Gynecologic oncology.

[120]  T. Soderling,et al.  A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1 , 1996, Molecular and cellular biology.

[121]  R. Métivier,et al.  The human estrogen receptor-alpha isoform hERalpha46 antagonizes the proliferative influence of hERalpha66 in MCF7 breast cancer cells. , 2005, Endocrinology.

[122]  Eva Enmark,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Human Estrogen Receptor �-Gene Structure, Chromosomal Localization, and Expression Pattern* , 2022 .

[123]  E. Lam,et al.  Estrogen receptor β2 negatively regulates the transactivation of estrogen receptor α in human breast cancer cells , 2007 .

[124]  J. Shine,et al.  Sequence and expression of human estrogen receptor complementary DNA. , 1986, Science.

[125]  D. Larsson,et al.  Membrane progesterone receptor gamma: Tissue distribution and expression in ciliated cells in the fallopian tube , 2007, Molecular reproduction and development.

[126]  C. Green,et al.  Two separate mechanisms for ligand-independent activation of the estrogen receptor. , 1997, Molecular endocrinology.

[127]  J. Weed,et al.  The progesterone therapy of human uterine leiomyomas. , 1949, The Journal of clinical endocrinology and metabolism.

[128]  A. Sahin,et al.  Molecular Cloning and Characterization of PELP1, a Novel Human Coregulator of Estrogen Receptor α , 2001 .

[129]  D. Moras,et al.  Crystal Structure of a Mutant hERα Ligand-binding Domain Reveals Key Structural Features for the Mechanism of Partial Agonism* , 2001, The Journal of Biological Chemistry.

[130]  N. Weigel,et al.  8-Bromo-Cyclic AMP Induces Phosphorylation of Two Sites in SRC-1 That Facilitate Ligand-Independent Activation of the Chicken Progesterone Receptor and Are Critical for Functional Cooperation between SRC-1 and CREB Binding Protein , 2000, Molecular and Cellular Biology.

[131]  Wendy Shelly,et al.  Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings , 2008, Obstetrical & gynecological survey.

[132]  J. Myers,et al.  The Classical Progesterone Receptor Associates with p42 MAPK and Is Involved in Phosphatidylinositol 3-Kinase Signaling inXenopus Oocytes* , 2001, The Journal of Biological Chemistry.

[133]  P. Chambon,et al.  Several regions of human estrogen receptor are involved in the formation of receptor-heat shock protein 90 complexes. , 1990, The Journal of biological chemistry.

[134]  M. Tsai,et al.  The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily , 1999, Molecular and Cellular Biology.

[135]  C. Nappi,et al.  Loss of oestrogen receptor β, high PCNA and p53 expression and aneuploidy as markers of worse prognosis in ovarian granulosa cell tumours , 2003, Histopathology.

[136]  D. Poirier,et al.  Antiestrogenic properties of keoxifene,trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells , 1989, Breast Cancer Research and Treatment.

[137]  G. Pelletier,et al.  Immunocytochemical Localization of Estrogen Receptors α and β in the Human Reproductive Organs , 2000 .

[138]  G. Pelletier,et al.  Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs. , 2000, The Journal of clinical endocrinology and metabolism.

[139]  B. Howard,et al.  The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases , 1996, Cell.

[140]  L. Hartmann,et al.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.

[141]  A. Shaaban,et al.  Declining Estrogen Receptor-&bgr; Expression Defines Malignant Progression of Human Breast Neoplasia , 2003, The American journal of surgical pathology.

[142]  J. Lees,et al.  Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. , 1992, The EMBO journal.

[143]  C. Lange,et al.  Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: Role of mitogen-activated protein kinases and cell cycle regulators , 2005, Steroids.

[144]  Yih-Leong Chang,et al.  The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. , 2005, The Journal of thoracic and cardiovascular surgery.

[145]  P. Thomas,et al.  Cell-surface expression, progestin binding, and rapid nongenomic signaling of zebrafish membrane progestin receptors α and β in transfected cells , 2006 .

[146]  T. Wiese,et al.  Rapid screening of environmental chemicals for estrogen receptor binding capacity. , 1998, Environmental health perspectives.

[147]  Shawn P Williams,et al.  A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. , 2007, Molecular endocrinology.

[148]  J. Chen,et al.  The SRC family of nuclear receptor coactivators. , 2000, Gene.

[149]  P. Sismondi,et al.  Role of Coactivators and Corepressors in Steroid and Nuclear Receptor Signaling: Potential Markers of Tumor Growth and Drug Sensitivity , 2001, The International journal of biological markers.

[150]  E. Lam,et al.  Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. , 2007, Cancer research.

[151]  M. Stallcup,et al.  Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. , 1998, Molecular Endocrinology.

[152]  K. Bramlett,et al.  Effects of selective estrogen receptor modulators (SERMs) on coactivator nuclear receptor (NR) box binding to estrogen receptors. , 2002, Molecular genetics and metabolism.

[153]  D. Edwards,et al.  Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. , 2001, Molecular cell.

[154]  P. Sigler,et al.  Atomic structure of progesterone complexed with its receptor , 1998, Nature.

[155]  Sandip K. Mishra,et al.  Potential Role of a Novel Transcriptional Coactivator PELP1 in Histone H1 Displacement in Cancer Cells , 2004, Cancer Research.

[156]  J. Gustafsson,et al.  Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. , 2001, Cancer research.

[157]  Xiaohong Gu Helix 12 in the human estrogen receptor (hER) is essential for the hER function by overcoming nucleosome repression in yeast , 2002, Journal of cellular biochemistry.

[158]  R. Sainson,et al.  A Conserved Mechanism for Steroid Receptor Translocation to the Plasma Membrane* , 2007, Journal of Biological Chemistry.

[159]  J. Schouten,et al.  Progesterone receptor polymorphism +331G/A is associated with a decreased risk of deep infiltrating endometriosis. , 2006, Human reproduction.

[160]  P. Thomas,et al.  Molecular characterization of three forms of putative membrane-bound progestin receptors and their tissue-distribution in channel catfish, Ictalurus punctatus. , 2005, Journal of molecular endocrinology.

[161]  C. Turck,et al.  Growth Factors Signal to Steroid Receptors through Mitogen-activated Protein Kinase Regulation of p160 Coactivator Activity* , 2001, The Journal of Biological Chemistry.

[162]  P. Thomas,et al.  Cell-surface expression, progestin binding, and rapid nongenomic signaling of zebrafish membrane progestin receptors alpha and beta in transfected cells. , 2006, The Journal of endocrinology.

[163]  Eric R. Prossnitz,et al.  A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling , 2005, Science.

[164]  Lei Li,et al.  Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[165]  K. Inoki,et al.  Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling , 2008, The EMBO journal.

[166]  P. Chambon,et al.  Ligand-dependent interaction between the estrogen receptor and the human homologues of SWI2/SNF2. , 1997, Gene.

[167]  D. Agard,et al.  Estrogen receptor pathways to AP-1 , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[168]  W. Zwart,et al.  PKA‐induced resistance to tamoxifen is associated with an altered orientation of ERα towards co‐activator SRC‐1 , 2007, The EMBO journal.

[169]  Charles David Jones,et al.  Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. , 1983, Life sciences.

[170]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[171]  V. D. Paola,et al.  Raloxifene in breast cancer prevention , 2008 .

[172]  B. O’Malley,et al.  Progesterone-binding components of chick oviduct. I. Preliminary characterization of cytoplasmic components. , 1970, The Journal of biological chemistry.

[173]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[174]  A. Shaaban,et al.  Risk for Subsequent Development of Breast Cancer: Authors' Reply , 2003 .

[175]  Richard G. W. Anderson,et al.  Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. , 2000, Circulation research.

[176]  Simak Ali,et al.  Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera , 2002, Oncogene.

[177]  T. Wu,et al.  Focus on endometrial and cervical cancer. , 2004, Cancer cell.

[178]  D. Edwards The Role of Coactivators and Corepressors in the Biology and Mechanism of Action of Steroid Hormone Receptors , 2000, Journal of Mammary Gland Biology and Neoplasia.

[179]  F. Penault-Llorca,et al.  Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. , 2000, Gynecologic oncology.

[180]  J. Graham,et al.  Progesterone receptors - animal models and cell signaling in breast cancer: Expression and transcriptional activity of progesterone receptor A and progesterone receptor B in mammalian cells , 2002, Breast Cancer Research.

[181]  P. Pujol,et al.  Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. , 2004, Endocrine-related cancer.

[182]  P. Chambon,et al.  Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex , 1990, Cell.

[183]  M. Beckmann,et al.  Early aberrant insulin‐like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen , 2008, International journal of cancer.

[184]  A. Takeshita,et al.  CBP-dependent and independent enhancing activity of steroid receptor coactivator-1 in thyroid hormone receptor-mediated transactivation , 1999, Molecular and Cellular Endocrinology.

[185]  N. Koszewski,et al.  Estrogen receptor phosphorylation. Hormonal dependence and consequence on specific DNA binding. , 1992, The Journal of biological chemistry.

[186]  T. Willson,et al.  Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition , 2002, Cell.

[187]  K. Bland,et al.  Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. , 2000, Molecular endocrinology.

[188]  Christopher J. Barnes,et al.  The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[189]  Luyang Sun,et al.  Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis , 2005, Nature.

[190]  P. Thomas,et al.  Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[191]  R. Kumar,et al.  Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. , 2001, The Journal of biological chemistry.

[192]  H. Burger,et al.  Molecular pathogenesis of granulosa cell tumours , 2002, Molecular and Cellular Endocrinology.

[193]  D. Livingston,et al.  The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[194]  Different expression of estrogen receptors α and β in human myometrium and leiomyoma during the proliferative phase of the menstrual cycle and after GnRHa treatment , 2001 .

[195]  B. Katzenellenbogen,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Role for Akt in Mediating the Estrogenic Functions of Epidermal Growth Factor and Insulin-Like Growth Factor I* , 2000 .

[196]  J. Gosden,et al.  Localization of the human oestrogen receptor gene to chromosome 6q24----q27 by in situ hybridization. , 1986, Cytogenetics and cell genetics.

[197]  K. Kovács,et al.  Comparative analysis of cyclin D1 and oestrogen receptor (α and β) levels in human leiomyoma and adjacent myometrium , 2001 .

[198]  M. Thun,et al.  No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[199]  R. Métivier,et al.  The Human Estrogen Receptor-α Isoform hERα46 Antagonizes the Proliferative Influence of hERα66 in MCF7 Breast Cancer Cells , 2005 .

[200]  H. Bryant,et al.  Raloxifene: A selective estrogen receptor modulator , 1994, Journal of Bone and Mineral Metabolism.

[201]  J. Thomsen,et al.  Mechanisms of estrogen action. , 2001, Physiological reviews.

[202]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[203]  H. Risch,et al.  PGR +331 A/G and Increased Risk of Epithelial Ovarian Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[204]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[205]  Carol S. Lim,et al.  Effect of initial subcellular localization of progesterone receptor on import kinetics and transcriptional activity. , 2005, Molecular pharmaceutics.

[206]  D. Philibert,et al.  RU 38486: a potent antiglucocorticoid in vitro and in vivo. , 1985, Journal of steroid biochemistry.